| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Esophageal squamous cell carcinoma (ESCC) is a poor prognosis tumor. Analysis of circulating tumor DNA (ctDNA) has demonstrated promising results for cancer diagnosis. However, ctDNA test hasn’t yet been an established tool in daily practice of cancer patients. This study aimed to investigate whether frequent tumor burden monitoring with ctDNA of individual tumor-specific mutations using digital PCR (dPCR) provides clinically useful information for ESCC patients. Mutation screening of primary ESCCs was performed with amplicon sequencing using originally-designed SCC panel, targeting 31 genes. The level of ctDNAs were evaluated using dPCR with originally-designed primer/probe sets for individual mutations. 27). This study demonstrated clinical validities of tumor burden monitoring with patient-specific ctDNA using dPCR in standard-of-care for ESCC patients including: 1) relapse and growth prediction, 2) treatment efficacy evaluation, and 3) relapse-free confirmation.
|
